Vaccination © Adobe Stock

On August 14, 2024, the WHO Director-General declared that the resurgence of mpox virus in the Democratic Republic of Congo and a growing number of African countries constituted a public health emergency of international concern.

In response, ANRS-MIE, an Inserm agency, provides a weekly watch on published scientific articles, to better understand the evolution of the epidemic and combat misinformation.

https://anrs.fr/fr/Cellules-Emergence/cellule-emergence-mpox-rdc-2023

Inserm and ANRS-MIE have been working on the epidemic since 2022

In 2022, following the occurrence of the first mpox epidemic outside endemic areas, the Inserm agency set up a crisis response mechanism for the research component dedicated to mpox.

9 studies on the characterization of the disease, prevention, treatments or vaccines in France and Africa have been financed and are currently underway; these studies are extremely useful and invaluable in view of the current upsurge.

Among the recent results published from one of these studies, the ANRS DOXYVAC trial has shown that rapid deployment of smallpox vaccination significantly reduces the risk of mpox.

These contents could be interesting :

Rapid rollout of smallpox vaccination reduces the risk of mpox

The ANRS DOXYVAC trial, promoted and funded by ANRS Emerging Infectious Diseases, and conducted by research teams from Inserm, AP-HP, Université Paris Cité and Sorbonne Université (France), shows that....